𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients

✍ Scribed by Thomas Kerbusch; John W. van Putten; Harry J. Groen; Alwin D. Huitema; Ron A. Mathôt; Jos H. Beijnen

Publisher
Springer
Year
2001
Tongue
English
Weight
201 KB
Volume
48
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Associations of ABCB1, ABCC2, and ABCG2
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer
✍ Ji-Youn Han; Hyeong-Seok Lim; Yeon-Kyeong Yoo; Eun Soon Shin; Yong Hoon Park; Su 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 2 views

## Abstract ## BACKGROUND. The authors investigated whether __ABCB1, ABCC2,__ and __ABCG2__ genetic polymorphisms affect pharmacokinetics (PK) of irinotecan and treatment outcome of patients with advanced nonsmall cell lung cancer (NSCLC). ## METHODS. Blood samples from 107 NSCLC patients treate

Simultaneous determination of gemcitabin
Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry
✍ Elena Marangon; Federica Sala; Orazio Caffo; Enzo Galligioni; Maurizio D'Incalci 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 420 KB 👁 1 views

## Abstract Gemcitabine, 2′,2′‐difluoro‐2′‐deoxycytidine (dFdC) is a pyrimidine antimetabolite employed against several human malignancies. It undergoes intracellular activation to the pharmacologically active triphosphate form (dFdCTP) and metabolic inactivation to the metabolite 2′,2′‐difluorodeo